NCI-N87 Transfection Kit (Gastric Carc. CRL-5822)

Description

Product Availability: In Stock (FedEx delivery within 2 business days).

Ordering: To place an order please use Add to Cart button (account not required).

---

Transfection Reagent for NCI-N87 Cells (Gastric Carcinoma Cells, CRL-5822)

• Two component formulation enhances lipid mediated transfection efficiency
• Optimized easy-to-use transfection protocol provided for transfection of siRNA, DNA, mRNA, and microRNA
• Kit includes Transfection Enhancer reagent and recommended transfection protocol
• High transfection efficacy in the presence of serum
• Expand your RNAi application with a reagent optimized for delivery of both siRNA and plasmid
• Reproducible transfection results
• Works well for standard reverse transfection and high-throughput applications
• Download in vitro NCI-N87 transfection protocol: [PDF]
• Download NCI-N87 CRISPR/Cas9 transfection protocol: [PDF]
• Download PowerPoint presentation for NCI-N87 cells transfection kit: [PPT]
• Developed and manufactured by Altogen Biosystems

Transfection Efficiency:

Reagent exhibits at least 91% transfection efficiency of siRNA delivery. Transfection efficiency was determined by qRT-PCR.

Transfection Protocol and MSDS:

Download Altogen Biosystems NCI-N87 Transfection Protocol: [PDF]

Download MSDS: [PDF]

NCI-N87 Cell Line:

NCI-N87 is a human gastric cancer cell line that was originally derived from a patient with poorly differentiated adenocarcinoma of the stomach. NCI-N87 cells are characterized by their high expression of the human epidermal growth factor receptor 2 (HER2), which is a protein that promotes cell growth and division. These cells also have mutations in the TP53 and APC genes, which are commonly found in gastric cancer and contribute to the development and progression of the disease. Researchers have used NCI-N87 cells to study various aspects of gastric cancer biology, including the signaling pathways that drive tumor growth and metastasis, the mechanisms of drug resistance, and the development of new therapeutic agents targeting HER2. This cell line has also been used to study the role of TP53 and APC in gastric cancer development and to test the efficacy of novel drugs targeting these pathways.

According to the American Cancer Society (ACS), gastric cancer was the most common cause of cancer fatalities in the United States until the late 1930s. However, in less developed countries with a general lack of access to refrigerated food storage, it remains a high mortality disease. Human tumor cell lines have proven to be invaluable models for studying cancer causes and properties. The NCI-N87 epithelial cell line was established from the stomach tissue of a male patient with gastric carcinoma, also known as stomach cancer. NCI-N87 cells have been derived from a metastatic site located in the liver. Also, the NCI-N87 cell line has been tested positive for myc and ERBB2 oncogenes. NCI-N87 cells express carcinoembryonic antigen (CEA) and TAG 72 surface glycoproteins. They were also found to express receptors for muscarinic cholinergic agents. In addition to being used in stomach cancer research, the NCI-N87 cell line is highly utilized in transfection. Commercially available transfection reagent kits can be ordered from Altogen Biosystems, including a two-component formulation NCI-N87 transfection reagent for gastric carcinoma cells.

Cell line mutations:

CNBD1	168975	37	8	88365898	88365898	Missense_Mutation	SNP	T	G
CACNA1B	774	37	9	140772533	140772533	Missense_Mutation	SNP	G	T
MUC16	94025	37	19	9070919	9070919	Silent	SNP	A	G
KIR3DL2	3812	37	19	55378031	55378031	Missense_Mutation	SNP	G	A
TTN	7273	37	2	179666974	179666974	Silent	SNP	G	A
GMPPA	29926	37	2	220371039	220371039	Missense_Mutation	SNP	G	A
TMEM63B	55362	37	6	44103069	44103069	Missense_Mutation	SNP	C	T
ABCB1	5243	37	7	87150134	87150134	Missense_Mutation	SNP	T	C
NOC2L	26155	37	1	881827	881827	Missense_Mutation	SNP	G	C
PLEKHN1	84069	37	1	906355	906355	Missense_Mutation	SNP	G	T
ERRFI1	54206	37	1	8064608	8064608	Missense_Mutation	SNP	T	C

Data:

Figure 1. siRNAs targeting Lamin A/C mRNA or non-silencing control siRNA were transfected into NCI-N87 cells following the recommended protocol. At 48 hours post-transfection the cells were analyzed by qRT-PCR for Lamin A/C gene expression levels. 18S rRNA levels were used to normalize the Lamin A/C data. Values are normalized to untreated sample. Data are means ± SD (n=4).

Figure 2. Protein expression of Lamin A in NCI-N87 cells. DNA plasmid expressing Lamin A or siRNA targeting Lamin A were transfected into NCI-N87 cells following Altogen Biosystems transfection protocol. At 72 hours post-transfection the cells were analyzed by Western Blot for protein expression levels (normalized by total protein, 10 µg of total protein loaded per each well). Untreated cells used as a negative control.

Altogen Biosystems:
Altogen Biosystems provides optimized transfection products for life science research applications. Transfection protocols are optimized for individual cell lines. Altogen Biosystems developed two types of in vivo delivery kits for animal research: Tissue-targeted reagents (delivery to liver, pancreas, and kidney tissues), and broad range in vivo delivery reagents (PEG-Liposome, Nanoparticle-based, Lipid-based, and Polymer-based kits). Advanced formulation of reagents and optimized transfection protocols provide efficient cellular delivery of proteins, DNA, RNA, and any other negatively charged molecules in vitro and in vivo. Read more about transfection technology at Altogen’s Transfection Resource.

Altogen Labs Research Services:

Altogen Labs provides GLP compliant contract research studies for preclinical research, IND applications, and drug development. Biology CRO services include: xenograft models (90+), development of stable cell lines, ELISA assay development, cell-based and tissue targeted RNAi studies, safety pharm/tox assays, and other studies (visit AltogenLabs.com).

Volume Options:

• 0.5 ml (Catalog #6870)
• 1.5 ml (Catalog #6871)
• 1.5 ml CRISPR (Catalog #2183)
• 8.0 ml (Catalog #7072)